Regulation of the G1/S phase of the cell cycle and alterations in the RB pathway in human lung cancer

Expert Review of Anticancer Therapy

Volumn 6, Issue 4, 2006, Pages 515-530

  Wikman, Harriet ^a   Kettunen, Eeva ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

Author keywords

CDK4; CDKN2A; Cyclin D1; DNA aberrations; Lung Cancer; Retinoblastoma

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; FLAVOPIRIDOL; IMATINIB; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; PROTEIN P16INK4A; ROSCOVITINE; TRASTUZUMAB; TUMOR SUPPRESSOR PROTEIN;

CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; EARLY DIAGNOSIS; ENZYME INHIBITION; GENE ACTIVATION; GENE AMPLIFICATION; GENE DELETION; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MITOGENICITY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TRACHEOBRONCHIAL TOILET; ANIMAL; DRUG EFFECT; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

ANIMALS; G1 PHASE; GENES, RETINOBLASTOMA; HUMANS; LUNG NEOPLASMS; S PHASE; SIGNAL TRANSDUCTION;

EID: 33746270787     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.4.515     Document Type: Review

References (174)

1. IARC. Tobacco smoke and involuntary smoking. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 83. Lyon, France (2002).
2. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nature Med. 10(8), 789-799 (2004).
3. Dimova DK, Dyson NJ. The E2F transcriptional network: old acquaintances with new faces. Oncogene 24(17), 2810-2826 (2005).
4. Lee MH, Yang HY. Regulators of G1 cyclin-dependent kinases and cancers. Cancer Metastasis Rev. 22(4), 435-449 (2003).
5. Pei XH, Xiong Y. Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues. Oncogene 24(17), 2787-2795 (2005).
6. Deshpande A, Sicinski P, Hinds PW. Cyclins and cdks in development and cancer: a perspective. Oncogene 24(17), 2909-2915 (2005).
7. INK4 protein is restricted to the subset of lung cancer lines that retains wild type RB. Oncogene 9(11), 3375-3378 (1994).
8. Betticher DC, White GR, Vonlanthen S et al. G1 control gene status is frequently altered in resectable non-small cell lung cancer. Int. J. Cancer 74(5), 556-562 (1997).
9. Malusecka E, Zborek A, Krzyzowska-Gruca S. Changes in expression of pRb, p16 and cyclin D1 in non-small cell lung cancer: an immunohistochemical study. Folia Histochem. Cytobiol. 37(1), 19-24 (1999).
10. Osada H, Takahashi T. Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Oncogene 21(48), 7421-7434 (2002).
11. Kaye FJ. RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer. Oncogene 21(45), 6908-6914 (2002).
12. Dobashi Y. Cell Cycle regulation and its aberrations in human lung carcinoma. Pathol. Int. 55(3), 95-105 (2005).
13. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA 68(4), 820-823 (1971).
14. Dannenberg JH, Schuijff L, Dekker M, van der Valk M, te Riele H. Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130. Genes Dev. 18(23), 2952-2962 (2004).
15. Gonzalo S, Blasco MA. Role of Rb family in the epigenetic definition of chromatin. Cell Cycle 4(6), 752-755 (2005).
16. Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nature Rev. Cancer 2(12), 910-917 (2002).
17. Meuwissen R, Linn SC, Linnoila RI et al. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 4(3), 181-189 (2003).
18. Uchida C, Miwa S, Kitagawa K et al. Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation. EMBO J. 24(1), 160-169 (2005).
19. Lozano G, Zambetti G. Gankyrin: an intriguing name for a novel regulator of p53 and RB. Cancer Cell 8(1), 3-4 (2005).
20. Gorgoulis VG, Zacharatos P, Kotsinas A et al. Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. Am. J. Pathol. 153(6), 1749-1765 (1998).
21. Kelley M, Nakagawa K, Steinberg S et al. Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. J. Natl Cancer Inst. 87(10), 756-761 (1995).
22. INK4a expression in resected non-small cell lung tumors. Cancer Res. 56(15), 3415-3420 (1996).
23. Sakaguchi M, Fujii Y, Hirabayashi H et al. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. Int. J. Cancer 65(4), 442-445 (1996).
24. Lingfei K, Pingzhang Y, Zhengguo L, Jianhua G, Yaowu Z. A study on p16, pRb, cdk4 and cyclinD1 expression in non-small cell lung cancers. Cancer Letts 14(130), 93-101 (1998).
25. Lonardo F, Rusch V, Langenfeld J, Dmitrovsky E, Klimstra DS. Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. Cancer Res. 59(10), 2470-2476 (1999).
26. Yuan J, Knorr J, Altmannsberger M et al. Expression of p16 and lack of pRB in primary small cell lung cancer. J. Pathol. 189(3), 358-362 (1999).
27. Dosaka-Akita H, Cagle P, Hiroumi H et al. Differential retinoblastoma and p16(INK4A) protein expression in neuroendocrine tumors of the lung. Cancer 88(3), 550-556 (2000).
28. Leversha MA, Fielding P, Watson S, Gosney JR, Field JK. Expression of p53, pRB, and p16 in lung tumours: a validation study on tissue microarrays. J. Pathol. 200(5), 610-619 (2003).
29. Harbour JW, Lai S-L, Whang-Peng J et al. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241, 353-357 (1988).
30. Yokota J, Akiyama T, Fung Y et al. Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung. Oncogene 3(4), 471-475 (1988).
31. Hensel C, Hsieh C, Gazdar A et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer Cancer Res. 50(10), 3067-3072 (1990).
32. Rygaard K, Sorenson G, Pettengill O, Cate C, Spang-Thomsen M. Abnormalities in structure and expression of the retinoblastoma gene in small cell lung cancer cell lines and xenografts in nude mice. Cancer Res. 50(17), 5312-5317 (1990).
33. Higashiyama M, Doi O, Kodama K, Yokouchi H, Tateishi R. Retinoblastoma protein expression in lung cancer: an immunohistochemical analysis. Oncology 51(6), 544-551 (1994).
34. Gouyer V, Gazzeri S, Brambilla E et al. Loss of heterozygosity at the RB locus correlates with loss of RB protein in primary malignant neuro-endocrine lung carcinomas. Int. J. Cancer 58(6), 818-824 (1994).
35. Shimizu E, Coxon A, Otterson G et al. RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene 9(9), 2441-2448 (1994).
36. Cagle P, el-Naggar A, Xu H, Hu S, Benedict W. Differential retinoblastoma protein expression in neuroendocrine tumors of the lung. Potential diagnostic implications. Am. J. Pathol. 150(2), 393-400 (1997).
37. Gouyer V, Gazzeri S, Bolon I et al. Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors. Am. J. Respir. Cell Mol. Biol. 18(2), 188-196 (1998).
38. Beasley MB, Lantuejoul S, Abbondanzo S et al. The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. Hum. Pathol. 34(2), 136-142 (2003).
39. Igarashi T, Jiang S, Kameya T et al. Divergent cyclin B1 expression and Rb/p16/cyclin D1 pathway aberrations among pulmonary neuroendocrine tumors. Mod. Pathol. 17(10), 1259-1267 (2004).
40. Peng W-X, Sano T, Oyama T, Kawashima O, Nakajima T. Large cell neuroendocrine carcinoma of the lung: a comparison with large cell carcinoma with neuroendocrine morphology and small cell carcinoma. Lung Cancer 47(2), 225-233 (2005).
41. Schauer I, Siriwardana S, Langan T, Sclafani R. Cyclin D1 overexpression vs. retinoblastomainactivation: implications for growth control evasion in non-small cell and small cell lung cancer. Proc. Natl Acad. Sci. USA 91(16), 7827-7831 (1994).
42. INK4-Cyclin D1) in preinvasive bronchial lesions. Clin. Cancer Res. 5(2), 243-250 (1999).
43. Mori N, Yokota J, Akiyama T et al. Variable mutations of the RB gene in small-cell lung carcinoma. Oncogene 5(11), 1713-1717 (1990).
44. Kashii T, Mizushima Y, Monno S, Nakagawa K, Kobayashi M. Gene analysis of K-, H-ras, p53, and retinoblastoma susceptibility genes in human lung cancer cell lines by the polymerase chain reaction/single-strand conformation polymorphism method. J. Cancer Res. Clin. Oncol. 120(3), 143-148 (1994).
45. Sachse R, Murakami Y, Shiraishi M, Hayashi K, Sekiya T. DNA aberrations at the retinoblastoma gene locus in human squamous cell carcinomas of the lung. Oncogene 9(1), 39-47 (1994).
46. Baldi A, Esposito V, De Luca A et al. Differential expression of Rb2/ p130 and p107 in normal human tissues and in primary lung cancer. Clin. Cancer Res. 3(10), 1691-1697 (1997).
47. Modi S, Kubo A, Ole H et al. Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer. Oncogene 19(40), 4632-4639 (2000).
48. Helin K, Holm K, Niebuhr A et al. Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma. Proc. Natl Acad. Sci. USA 94(13), 6933-6938 (1997).
49. Xue Jun H, Gemma A, Hosoya Y et al. Reduced transcription of the RB2/ p130 gene in human lung cancer. Mol. Carcinog. 38(3), 124-129 (2003).
50. Cinti C, Macaluso M, Giordano A. Tumor-specific exon 1 mutations could be the 'hit event' predisposing Rb2/p130 gene to epigenetic silencing in lung cancer. Oncogene 24(38) 5821-5826 (2005).
51. Caputi M, Groeger AM, Esposito V et al. Loss of pRb2/p130 expression is associated with unfavorable clinical outcome in lung cancer. Clin. Cancer Res. 8(12), 3850-3856 (2002).
52. Wang TC, Cardiff RD, Zukerberg L et al. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369(6482), 669-671 (1994).
53. Sicinski P, Donaher J, Parker S et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82(4). 621-630 (1995).
54. Kozar K, Ciemerych MA, Rebel VI et al. Mouse development and cell proliferation in the absence of D-cyclins. Cell 118(4), 477-491 (2004).
55. Geng Y, Whoriskey W, Park M et al. Rescue of cyclin D1 deficiency by knockin cyclin E. Cell 97(6), 767-777 (1999).
56. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 411(6841), 1017-1021 (2001).
57. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: cyclin D1: normal and abnormal functions. Endocrinology 145(12), 5439-5447 (2004).
58. Betticher D, Heighway J, Thatcher N, Hasleton P. Abnormal expression of CCND1 and RB1 in resection margin epithelia of lung cancer patients. Br. J. Cancer 75(12), 1761-1768 (1997).
59. Marchetti A, Doglioni C, Barbareschi M et al. Cyclin D1 and retinoblastoma susceptibility gene alterations in non-small cell lung cancer. Int. J. Cancer 75(2), 187-192 (1998).
60. Donnellan R, Chetty R. Cyclin D1 and human neoplasia. Mol. Pathol. 51(1), 1-7 (1998).
61. Reissmann P, Koga H, Figlin R et al. Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. J Cancer Res. Clin. Oncol. 125(2), 61-70 (1999).
62. Schraml P, Kononen J, Bubendorf L et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin. Cancer Res. 5(8), 1966-1975 (1999).
63. Kukoski R, Blonigen B, Macri E et al. p27 and cyclin E/D2 associations in testicular germ cell tumors: implications for tumorigenesis. Appl. Immunohistochem. Mol. Morphol. 11(2), 138-143 (2003).
64. Kettunen E, Nissen AM, Ollikainen T et al. Gene expression profiling of malignant mesothelioma cell lines: cDNA array study. Int. J. Cancer 91(4), 492-496 (2001).
65. Virmani A, Rathi A, Heda S et al. Aberrant methylation of the cyclin D2 promoter in primary small cell, nonsmall cell lung and breast cancers. Int. J. Cancer 107(3), 341-345 (2003).
66. Girard L, Zochbauer-Muller S, Virmani AK, Gazdar AF, Minna JD. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res. 60(17), 4894-4906 (2000).
67. Usuda H, Saito T, Emura I, Naito M. Immunohistochemistry of cyclin D3 in pulmonary carcinomas. Virchows Arch. 428(3), 159-163 (1996).
68. Rosenwald IB, Kaspar R, Rousseau D et al. Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels. J. Biol. Chem. 270(36), 21176-21180 (1995).
69. Ratschiller D, Heighway J, Gugger M et al. Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J. Clin. Oncol. 21(11), 2085-2093 (2003).
70. Brambilla E, Moro D, Gazzeri S, Brambilla C. Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance. J. Pathol. 188(4), 351-360 (1999).
71. Lantuejoul S, Soria JC, Morat L et al. Telomere shortening and telomerase reverse transcriptase expression in preinvasive bronchial lesions. Clin. Cancer Res. 11(5), 2074-2082 (2005).
72. Ho Y-S, Chen C-H, Wang Y-J et al. Tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) induces cell proliferation in normal human bronchial epithelial cells through NF-κB activation and cyclin D1 upregulation. Toxicol. Appl. Pharmacol. 205(2), 133-148 (2005).
73. Dobashi Y, Goto A, Fukayama M, Abe A, Ooi A. Overexpression of cdk4/ cyclin D1, a possible mediator of apoptosis and an indicator of prognosis in human primary lung carcinoma. Int. J. Cancer 110(4), 532-541 (2004).
74. Ikehara M, Oshita F, Ito H et al. Expression of cyclin D1 but not of cyclin E is an indicator of poor prognosis in small adenocarcinomas of the lung. Oncol. Rep. 10(1), 137-139 (2003).
75. Dworakowska D, Jassem E, Jassem J et al. Prognostic value of cyclin D1 overexpression in correlation with pRb and p53 status in non-small cell lung cancer (NSCLC). J. Cancer Res. Clin. Oncol. 131(7), 479-485 (2005).
76. Burke L, Flieder D, Guinee D et al. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. Clin. Cancer Res. 11(1), 232-241 (2005).
77. INK4a binding domain of CDK4 in familial melanoma. Nature Genet. 12(1), 97-99 (1996).
78. Meyerson M, Harlow E. Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol. Cell Biol. 14(3), 2077-2086 (1994).
79. Sotillo R, Garcia JF, Ortega S et al. Invasive melanoma in Cdk4-targeted mice. Proc. Natl Acad. Sci. USA 98(23), 13312-13317 (2001).
80. Rodriguez-Puebla ML, Miliani de Marval PL, LaCava M et al. Cdk4 deficiency inhibits skin tumor development but does not affect normal keratinocyte proliferation. Am. J. Pathol. 161(2), 405-411 (2002).
81. Miliani de Marval P, Macias E, Conti C, Rodriguez-Puebla M. Enhanced malignant tumorigenesis in Cdk4 transgenic mice. Oncogene 23(10), 1863-1873 (2004).
82. Zhou JX, Niehans GA, Shar A et al. Mechanisms of G1 checkpoint loss in resected early stage non-small cell lung cancer. Lung Cancer 32(1), 27-38 (2001).
83. Rane SG, Dubus P, Mettus RV et al. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia. Nature Genet. 22(1), 44-52 (1999).
84. Tsutsui T, Hesabi B, Moons DS et al. Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. Mol. Cell Biol. 19(10), 7011-7019 (1999).
85. Malumbres M, Sotillo R, Santamaria D et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 118(4), 493-504 (2004).
86. Bouchard C, Thieke K, Maier A et al. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 18(19), 5321-5333 (1999).
87. Hermeking H, Rago C, Schuhmacher M et al. Identification of CDK4 as a target of c-MYC. Proc. Natl Acad. Sci. USA 97(5), 2229-2234 (2000).
88. Miliani de Marval PL, Macias E, Rounbehler R et al. Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues. Mol. Cell Biol. 24(17), 7538-7547 (2004).
89. Pawar SA, Szentirmay MN, Hermeking H, Sawadogo M. Evidence for a cancer-specific switch at the CDK4 promoter with loss of control by both USF and c-Myc. Oncogene 23(36), 6125-6135 (2004).
90. Sugimoto M, Nakamura T, Ohtani N et al. Regulation of CDK4 activity by a novel CDK4-binding protein, p34(SEI-1), Genes Dev. 13(22), 3027-3033 (1999).
91. Matsuura I, Denissova NG, Wang G et al. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 430(6996), 226-231 (2004).
92. Chen X, Oh SW, Zheng Z et al. Cyclin D-Cdk4 and cyclin E-Cdk2 regulate the Jak/STAT signal transduction pathway in Drosophila. Dev. Cell 4(2), 179-190 (2003).
93. Volm M, Koomagi R, Rittgen W. Clinical implications of cycin, cyclin-dependent kinases, RB and E2F1 in squamous-cell lung carcinoma. Int. J. Cancer 79(3), 294-299 (1998).
94. Volm M, Koomagi R. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival. Br. J. Cancer 82(10), 1747-1754 (2000).
95. INK4, and Rb expression in the prognosis of bronchioloalveolar carcinomas. Respiration 72(1), 68-73 (2005).
96. Wikman H, Nymark P, Vayrynen A et al. CDK4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer. Genes Chromosomes Cancer 42(2), 193-199 (2005).
97. Shah L, Walter KL, Borczuk AC et al. Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. Cancer 101(7), 1632-1638 (2004).
98. Zhao X, Weir BA, LaFramboise T et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res. 65(13), 5561-5570 (2005).
99. Szymanska J, Serra M, Skytting B et al. Genetic imbalances in 67 synovial sarcomas evaluated by comparative genomic hybridization. Genes Chromosomes Cancer 23(3), 213-219 (1998).
100. Forus A, Larramendy ML, Meza-Zepeda LA et al. Dedifferentiation of a well-differentiated liposarcoma to a highly malignant metastatic osteosarcoma: amplification of 12q14 at all stages and gain of 1q22-q24 associated with metastases. Cancer Genet. Cytogenet. 125(2), 100-111 (2001).
101. Weber-Hall S, Anderson J, McManus A et al. Gains, losses, and amplification of genomic material in rhabdomyosarcoma analyzed by comparative genomic hybridization. Cancer Res. 56(14), 3220-3224 (1996).
102. Soufir N, Avril MF, Chompret A et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum. Mol. Genet. 7(2), 209-216 (1998).
103. Mori N, Yang R, Kawamata N et al. Absence of R24C mutation of the CDK4 gene in leukemias and solid tumors. Int. J. Hematol. 77(3), 259-262 (2003).
104. Costello JF, Plass C, Arap W et al. Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res. 57(7), 1250-1254 (1997).
105. Hirai Y, Utsugi K, Takeshima N et al. Putative gene loci associated with carcinogenesis and metastasis of endocervical adenocarcinomas of uterus determined by conventional and array-based CGH. Am. J. Obstet. Gynecol. 191(4), 1173-1182 (2004).
106. Takada H, Imoto I, Tsuda H et al. Screening of DNA copy-number aberrations in gastric cancer cell lines by array-based comparative genomic hybridization. Cancer Sci. 96(2), 100-110 (2005).
107. Corcoran MM, Mould SJ, Orchard JA et al. Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations. Oncogene 18(46), 6271-6277 (1999).
108. Balsara BR, Testa JR. Chromosomal imbalances in human lung cancer. Oncogene 21(45), 6877-6883 (2002).
109. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366(6456), 704-707 (1993).
110. Latres E, Malumbres M, Sotillo R et al. Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. EMBO J. 19(13), 3496-3506 (2000).
111. INK4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413(6851), 86-91 (2001).
112. Ciemerych MA, Sicinski P. Cell cycle in mouse development. Oncogene 24(17), 2877-2898 (2005).
113. INK4a confers susceptibility to metastatic melanoma in mice. Nature 413(6851), 83-86 (2001).
114. Stone S, Jiang P, Dayananth P et al. Complex structure and regulation of the P16 (MTS1) locus. Cancer Res. 55(14), 2988-2994 (1995).
115. Tanaka H, Fujii Y, Hirabayashi H et al. Disruption of the RB pathway and cell-proliferative activity in non-small-cell lung cancers. Int. J. Cancer 79(2), 111-115 (1998).
116. Kashiwabara K, Oyama T, Sano T, Fukuda T, Nakajima T. Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non-small cell lung cancers. Int. J. Cancer 79(3), 215-220 (1998).
117. Toyooka S, Toyooka KO, Maruyama R et al. DNA methylation profiles of lung tumors. Mol. Cancer Ther. 1(1), 61-67 (2001).
118. Sanchez-Cespedes M, Decker PA, Doffek KM et al. Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers. Cancer Res. 61(5), 2092-2096 (2001).
119. Yanagawa N, Tamura G, Oizumi H et al. Frequent epigenetic silencing of the p16 gene in non-small cell lung cancers of tobacco smokers. Jpn. J. Cancer Res. 93(10), 1107-1113 (2002).
120. INK4A inactivation in non-small-cell lung cancers. Oncogene 16(4), 497-504 (1998).
121. Jacobs JJ, Scheijen B, Voncken JW et al. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev. 13(20), 2678-2690 (1999).
122. INK4a and pRb expression in resectable non-small cell lung cancer. Int. J. Oncol. 16(5), 951-957 (2000).
123. Ahrendt SA, Chow JT, Xu LH et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J. Natl Cancer Inst. 91(4), 332-339 (1999).
124. Spanakis NE, Gorgoulis V, Mariatos G et al. Aberrant p16 expression is correlated with hemizygous deletions at the 9p21-22 chromosome region in non-small cell lung carcinomas. AntiCancer Res. 19(3A), 1893-189 (1999).
125. Chen JT, Chen YC, Wang YC, Tseng RC. Chen CY. Alterations of the p16(INK4a) gene in resected nonsmall cell lung tumors and exfoliated cells within sputum. Int. J. Cancer 98(5), 724-731 (2002).
126. Tanaka R, Wang D, Morishita Y et al. Loss of function of p16 gene and prognosis of pulmonary adenocarcinoma. Cancer 103(3), 608-615 (2005).
127. Sanchez-Cespedes M, Ahrendt SA, Piantadosi S et al. Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res. 61(4), 1309-1313 (2001).
128. Hayward N. New developments in melanoma genetics. Curr. Oncol. Rep. 2(4), 300-306 (2000).
129. Sanchez-Cespedes M, Reed AL, Buta M et al. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer. Oncogene 18(43), 5843-5849 (1999).
130. Niklinska W, Chyczewski L, Laudanski J, Chyczewska E, Niklinski J. Detection of p16 abnormalities in early-stage non-small cell lung cancer. Folia Histochem. Cytobiol. 39(Suppl. 2) 30-32 (2001).
131. Yanagawa N, Tamura G, Oizumi H et al. Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci. 94(7), 589-592 (2003).
132. Kim DH, Kim JS, Ji YI et al. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res. 63(13), 3743-3746 (2003).
133. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nature Rev. Cancer 4(9), 707-717 (2004).
134. Divine KK, Pulling LC, Marron-Terada PG et al. Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers. Int. J. Cancer 114(3), 400-405 (2005).
135. Kim DH, Nelson HH, Wiencke JK et al. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res. 61(8), 3419-3424. (2001).
136. Toyooka S, Suzuki M, Maruyama R et al. The relationship between aberrant methylation and survival in non-small-cell lung cancers. Br. J. Cancer 91(4), 771-774 (2004).
137. Belinsky SA, Nikula KJ, Palmisano WA et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl Acad. Sci. USA 95(20), 11891-11896 (1998).
138. INK4a gene promoter region in preinvasive bronchial lesions: a prospective study in high-risk patients without invasive cancer. Int. J. Cancer 100(2), 189-193 (2002).
139. Breuer RH, Snijders PJ, Sutedja GT et al. Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions. Lung Cancer 48(3), 299-306 (2005).
140. Jarmalaite S, Kannio A, Anttila S, Lazutka JR, Husgafvel-Pursiainen K. Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer. Int. J. Cancer 106(6), 913-918 (2003).
141. Palmisano WA, Divine KK, Saccomanno G et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60(21), 5954-5958 (2000).
142. Kawamata N, Miller CW, Koeffler HP. Molecular analysis of a family of cyclin-dependent kinase inhibitor genes (p15/MTS2/INK4b and p18/INK4c) in non-small cell lung cancers. Mol. Carcinog. 14(4), 263-268 (1995).
143. Kurakawa E, Shimamoto T, Utsumi K et al. Hypermethylation of p16(INK4a) and p15(INK4b) genes in non-small cell lung cancer. Int. J. Oncol. 19(2), 277-281 (2001).
144. Chaussade L, Eymin B, Brambilla E, Gazzeri S. Expression of p15 and p15.5 products in neuroendocrine lung tumours: relationship with p15(INK4b) methylation status. Oncogene 20(45), 6587-6596 (2001).
145. Furonaka O, Takeshima Y, Awaya H et al. Aberrant methylation of p14(ARF), p15(INK4b) and p16(INK4a) genes and location of the primary site in pulmonary squamous cell carcinoma. Pathol. Int. 54(8), 549-555 (2004).
146. Rusin MR, Okamoto A, Chorazy M et al. Intragenic mutations of the p16(INK4), p15(INK4B) and p18 genes in primary non-small-cell lung cancers. Int. J. Cancer 65(6), 734-739 (1996).
147. Saitoh G, Sugio K, Ishida T, Sugimachi K. Prognostic significance of p21waf1, cyclin D1 and retinoblastoma expression detected by immunohistochemistry in non-small cell lung cancer. Oncol. Rep. 8(4), 737-743 (2001).
148. Gugger M, Kappeler A, Vonlanthen S et al. Alterations of cell cycle regulators are less frequent in advanced non-small cell lung cancer than in resectable tumours. Lung Cancer 33(2-3), 229-239 (2001).
149. Jin M, Inoue S, Umemura T et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer 34(2), 207-218 (2001).
150. Buolamwini JK. Cell cycle molecular targets in novel anticancer drug discovery. Curr. Pharm. Des. 6(4), 379-392 (2000).
151. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nature Rev. Cancer 1(3), 222-231 (2001).
152. Senderowicz AM. Small-molecule cyclin-dependent kinase modulators. Oncogene 22(42), 6609-6620 (2003).
153. Shapiro GI. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin. Cancer Res. 10(12 Pt.2), 4270s-4275s (2004).
154. Sausville EA, Arbuck SG, Messmann R et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J. Clin. Oncol. 19(8), 2319-2333 (2001).
155. Soni R, O'Reilly T, Furet P et al. Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. J. Natl Cancer Inst. 93(6), 436-446 (2001).
156. Horowitz JM, Park SH, Bogenmann E et al. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc. Natl Acad. Sci. USA 87(7), 2775-2779 (1990).
157. Safar AM, Spencer H III, Su X et al. Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin. Cancer Res. 11(12), 4400-4405 (2005).
158. Grote HJ, Schmiemann V, Geddert H et al. Aberrant promoter methylation of p16(INK4a), RARB2 and SEMA3B in bronchial aspirates from patients with suspected lung cancer. Int. J. Cancer 116(5), 720-725 (2005).
159. Kim YT, Lee SH, Sung SW, Kim JH. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection? Ann. Thorac. Surg. 79(4), 1180-1188 (2005).
160. Fujiwara K, Fujimoto N, Tabata M et al. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin. Cancer Res. 11(3), 1219-1225 (2005).
161. INK4a promoter hypermethylation in human papillomavirus-infected female lung cancer in Taiwan. Int. J. Cancer 113(3), 440-445 (2005).
162. INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin. Cancer Res. 10(18 Pt. 1), 6119-6125 (2004).
163. Kim H, Kwon YM, Kim JS et al. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. J. Clin. Oncol. 22(12), 2363-2370 (2004).
164. Destro A, Bianchi P, Alloisio M et al. K-ras and p16(INK4A)alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers. Lung Cancer 44(1), 23-32 (2004).
165. Gonzalez-Quevedo R, Garcia-Aranda C, Moran A et al. Differential impact of p16 inactivation by promoter methylation in non-small cell lung and colorectal cancer: clinical implications. Int. J. Oncol. 24(2), 349-355 (2004).
166. INK4a in Chinese lung cancer patients: biological and clinical implications. Carcinogenesis 24(12), 1897-1901 (2003).
167. Konno S, Morishita Y, Fukasawa M et al. Anthracotic index and DNA methylation status of sputum contents can be used for identifying the population at risk of lung carcinoma. Cancer 102(6), 348-354 (2004).
168. Toyooka S, Maruyama R, Toyooka KO et al. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int. J. Cancer 103(2), 153-160 (2003).
169. Harden SV, Tokumaru Y, Westra WH et al. Gene promoter hypermethylation in tumors and lymph nodes of Stage I lung cancer patients. Clin. Cancer Res. 9(4), 1370-1375 (2003).
170. Chan EC, Lam SY, Tsang KW et al. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage. Clin. Cancer Res. 8(12), 3741-3746 (2002).
171. Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 277(5334), 2002-2004 (1997).
172. Soria JC, Rodriguez M, Liu DD et al. Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Res. 62(2), 351-355 (2002).
173. Zochbauer-Muller S, Fong KM, Virmani AK et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 61(1), 249-255 (2001).
174. Kersting M, Friedl C, Kraus A et al. Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J. Clin. Oncol. 18(18), 3221-229 (2000).